The companies were the latest to agree to sell drugs to Medicaid and directly to consumers at discounted prices. President ...

The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with ...

Merck MRK is expected to face some notable headwinds over the next few years that could affect its long-term growth outlook, ...

The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's cholesterol pill ...

Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few years. In the meantime, the company's performance leaves a lot to be desired.

Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish ...

The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” ...

Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evaxion and no change to its cash ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

We recently published 12 Stocks on Jim Cramer’s Radar . Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new subcutaneous formulation of ...